Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection Site Pain of Semaglutide Pens DV3396 vs PDS290
NCT04007107Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novo Nordisk. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04007107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007107.